m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03668)
Name
IKI-1
Synonyms
IKK inhibitors (cancer); I kappa B kinase inhibitors (cancer), Pfizer; IKK inhibitor (cancer), Wyeth; IKK inhibitors (cancer), Pfizer
    Click to Show/Hide
Status
Investigative
TTD Drug ID
D03JMF
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Inhibitor of nuclear factor kappa-B kinase alpha (IKKA)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Inhibitor of nuclear factor kappa-B kinase alpha (IKKA) is a therapeutic target for IKI-1. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of IKI-1 through regulating the expression of Inhibitor of nuclear factor kappa-B kinase alpha (IKKA). [1], [2]
References
Ref 1 METTL3 regulates alternative splicing of MyD88 upon the lipopolysaccharide-induced inflammatory response in human dental pulp cells. J Cell Mol Med. 2018 May;22(5):2558-2568. doi: 10.1111/jcmm.13491. Epub 2018 Mar 4.
Ref 2 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.